brain/
← all entities
entityISRGstock-market

Intuitive Surgical

Notes

Intuitive Surgical

One-line summary: Dominant robotic surgery platform (da Vinci + Ion); Q1 2026 showed 16% procedure growth led by da Vinci 5 utilization gains and OUS reimbursement expansion, with China as the primary structural headwind. Q2 FY2026 (reported 2026-07-16) is the resolution of the Q1 ACA watch: US da Vinci growth moderated to 12% (from 14%) on deferrable procedures + "changes in patient coverage and premium dynamics," and US bariatric cases fell high-single-digits on rising GLP-1 usage — so ISRG is now the downstream medtech node of both healthcare forcing functions.

What it is

Intuitive Surgical makes the da Vinci robotic surgery platform (used in general surgery, gynecology, urology) and the Ion endoluminal system for minimally invasive lung biopsies. Revenue model: capital sales of systems + high-margin recurring procedure instruments and accessories. The installed base of ~10,000 da Vinci systems globally creates a durable revenue stream tied to procedure volume.

Why it matters to stock-market

ISRG is a proxy for robotic surgery adoption rate and international reimbursement policy expansion. The da Vinci 5 platform upgrade cycle is the near-term volume driver. OUS reimbursement policy (especially Japan and Europe) acts as a forcing function: new procedure codes directly unlock volume without requiring new capital sales. China is a structural headwind (domestic competition + delayed reimbursement) that constrains the OUS growth narrative.

Key facts

Q2 FY2026 update (the ACA watch resolves; GLP-1 substitution quantified)

Reported 2026-07-16. Note: 2026-07-16-earnings-isrg-q2-fy2026 is partial — only quoted strings are verbatim management speech; unquoted causal phrasing is the extractor's paraphrase, and as-reported numbers.

  • US da Vinci growth moderated to 12% (from 14% in Q1), concentrated in deferrable procedures — the Q1 ACA watch materialized. As reported in 2026-07-16-earnings-isrg-q2-fy2026 (⚠ partial transcript — only the internally-quoted fragment below is verbatim; the rest is the extractor's paraphrase of management's position + as-reported numbers): US da Vinci growth was 12%, with the moderation concentrated in procedures that can be deferred, and some customers cited "changes in patient coverage and premium dynamics may be affecting when patients seek care." CFO Jamie Samath framed the cause (paraphrase) as a combination of some ACA impact and the law of large numbers. Downstream corroborating node of aca-subsidy-cliff-to-deferred-procedure-volume.
  • US bariatric cases declined high-single-digits, attributed to rising GLP-1 usage — first-party GLP-1 substitution. As reported in 2026-07-16-earnings-isrg-q2-fy2026 (partial — paraphrase/as-reported, not a verbatim quote): US da Vinci bariatric cases declined high-single-digits in the quarter, which management attributed to rising GLP-1 usage. First-party confirmation of glp1-substitution-to-bariatric-surgery-decline.
  • Headline Q2: total procedures +16%; da Vinci procedures +15%; Ion +36% (48,000, >400,000 cumulative); revenue +19% to $2.89B (recurring 85%); non-GAAP EPS +28%; non-GAAP gross margin 70% (68.7% ex a $36M IEIPA tariff-refund benefit). Per 2026-07-16-earnings-isrg-q2-fy2026.
  • Guidance held, guided to midpoint: FY2026 da Vinci procedure-growth 13.5–15.5%, "closer to the midpoint" (~14.5%, below ~15.3% consensus); gross-margin range raised to 68–69%. Q3 has tougher US comps. Shares fell despite the revenue/EPS beat.
  • OUS da Vinci +20% (Europe +20%, Asia +20%, RoW +22%); China "remains challenging with lower tender activity and increased domestic competition" — and a new China VBP headwind: Dave Rosa believes surgical robotics "will be part of" China's new centralized value-based-procurement program (declined to compare it to VBP directly).
  • New platform leg: submitted an FDA 510(k) for a "foundational non-commercial next-generation flexible robotic endoscope system for use in the gastrointestinal tract" — extends the platform beyond soft-tissue surgery (Ion is the precedent).
  • Capital environment: ~70% of US systems acquired under leasing; ~half of Q2 US placements were trades (don't expand installed base); US utilization +3%. Leadership note: Dave Rosa is now CEO (not Gary Guthart).
  • Japan reimbursement catalyst (June 1): inguinal hernia is "the largest procedure with newer reimbursement" — an OUS volume unlock to watch.

Related

Referenced by
Mechanisms
ACA enhanced-subsidy expiry → premium doubling → marketplace risk-pool shrink → deferred elective procedures + uncompensated care → for-profit hospital volume decline & guidance cuts (HCA/THC/UHS/CYH), ISRG corroboratingGLP-1 efficacy ~ bariatric-surgery-like + Medicare Bridge access → patients substitute drugs for surgery → structural bariatric-surgery volume decline → ISRG bariatric segment down (loser) / LLY obesity TAM up (winner)
Concepts
ACA subsidy cliff: enhanced-premium-credit expiration as a coverage-and-demand forcing function